Abstract: The present invention relates to a polypeptide which comprises or consists of—a first sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 55 to 67 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a second sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 85 to 101 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a third sequence consisting of at least 8 contiguous amino acid residues selected from within the sequence extending from amino acid residues 111 to 127 of the PD-L1 protein, and at most 30 contiguous amino acid residues selected from within the complete sequence of the PD-L1 protein; and/or—a fourth sequence consisting of at least 8 contiguous amino acid resi
Type:
Application
Filed:
March 5, 2019
Publication date:
December 23, 2021
Applicants:
Peptinov SAS, Conservatoire National des Arts et Metiers
Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.
Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.
Abstract: The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X1-S-D-I-F-X2-G-E-P-X3-L-X4-P-X5-X6-X7-X8-X9-Q-L (SEQ ID NO: 13).
Abstract: The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence.